The role of serum adhesion molecules and vascular endothelial growth factor in lung cancer patients;Akciǧer kanserli hastalarda serum adezyon molekülleri ile vasküler epiteyal büyüme fatktörünün rolü

Turkiye Klinikleri Journal of Medical Sciences

Volumn 30, Issue 4, 2010, Pages 1214-1219

  Yurdakul, Ahmet Selim ^a   Han, Elif Reyhan ^a   Bukan, Neslihan ^a   Öztürk, Can ^a  

^a GAZI UNIVERSITY FACULTY OF MEDICINE   (Turkey)

Author keywords

Intercellular adhesion molecule 1; Lung; Matrix metalloproteinases; Vascular endothelial growth factors

Indexed keywords

COLLAGENASE 3; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; VASCULOTROPIN;

ADULT; AGE; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; DISTANT METASTASIS; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; SMOKING; SURVIVAL RATE; SURVIVAL TIME;

EID: 77957279971     PISSN: 13000292     EISSN: None     Source Type: Journal    
DOI: 10.5336/medsci.2009-13128     Document Type: Article

References (29)

1. Parkin DM, Pisoni P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49(1):33-64.
2. Parkin DM. The global burden of cancer. Semin Cancer Biol 1998;8(4):219-35.
3. Laack E, Köhler A, Kugler C, Dierlamm T, Knuffmann C, Vohwinkel G, et al. Pretreatment serum levels of matrix metalloproteinase- 9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol 2002;13(10):1550-7.
4. Spiro SG, Porter JC. Lung cancer-Where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med 2002;166(9):1166-96.
5. Goksel T, Akkoclu A. Turkish Thoracic Society, Lung and Pleural Malignancies Study Group. Pattern of lung cancer in Turkey, 1994-1998. Respiration 2002;69(3):207-10.
6. Bonomi P. Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Semin Oncol 2002;29(1):78-86.
7. De vita F, Infusino S, Auriemma A, Orditura M, Catalano G. Circulating levels of soluable intersellular adhesion molecule-1 in non-small cell lung cancer patients. Oncol Rep 1998;5 (2):393-6.
8. Kamiyoshihara K, Kawashima O, Otani Y, Morishita Y. Clinical significance of the preoperative serum- soluable intersellular adhesion molecule-1 in non-small cell lung cancer. J Cardiovasc Surg 2002;43(5):729-34.
9. Hrabec E, Strek M, Nowak D, Hrabec Z. Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer. Resp Med 2001;95(1):1-4.
10. Mountain CF. The international system for staging lung cancer. Semin Surg Oncol 2000;18(2):106-15.
11. Takigawa N, Segawa Y, Fujimoto N, Hotta K, Eguchi K. Elevated vascular endo¬thelial growth factor in sera of patients with lung cancer. Anticancer Res 1998;18(2):251-4.
12. Farias E, Ranuncolo S, Cresta C, Specterman S, Armanasco E, Varela M, et al. Plasma metalloproteinase activity is enhanced in the globulin fraction of breast and lung cancer patients. Int J Cancer 2000;89(4):389-94.
13. Massova I, Kotra LP, Fridman R, Mobashery S. Matrix metalloproteinases: structures, evolution and diversification. FASEB J 1998;12 (12):1075-95.
14. Crawford HC, Matrisian LM. Mechanisms controlling the transcription of matrix metalloprote3inase genes in normal and neoplastic cells. Enzyme Protein 1996;49(1-3):20-37.
15. Kleiner DE, Stetler-Stevenson WG. Matrix metalloproteinases and metastasis. Cancer Chemother Pharmacol 1999;43(Suppl):S42-51.
16. Gress TM, Müller-Pillasch F, Lerch MM, Friess H, Büchler M, Adler G. Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995;62(4):407-13.
17. Iwata H, Kobayashi S, Iwase H, Masaoka A, Fujimoto N, Okada Y. Production of matrix metallo¬proteinases and tissue inhibitors of metalloproteinases in human breast carcinomas. Jpn J Cancer Res 1996;87(6):602-11.
18. Ueda Y, Imai K, Tsuchiya H, Fujimoto N, Nakanishi I, Katsuda S, et al. Matrix metalloproteinase 9 (gelatinase B) is expressed in multinucleated giant cells of human giant cell tumor of bone and is associated with vascular invasion. Am J Pathol 1996;148(2):611-22
19. Takahashi Y, Kitadai Y, Bucana CD, Cleary KR, Ellis LM. Expression of vascular endothelial growth factor and its receptor: KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995;55(18):3964-8.
20. Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptor in breast cancer. Hum Pathol 1995;26(1):86-91.
21. Kimura H, Konsihi K, Nukui T, Kaji M, Maeda K, Yabushita K, et al. Prognostic significance of expression of thymidine phosphorylase and vascular endothelial growth factor in human gastric carcinoma. J Surg Oncol 2001;76(1): 31-6.
22. Şahin E, Ökten I. [Effects of the angiogenetic factors on the esophageal neoplasms prognosis]. Turkiye Klinikleri J Surg Med Sci 2007;3(29):24-8.
23. Li L, Wang L, Zhang W, Tang B, Zhang J, Song H, et al. Correlation of serum VEGF levels with clinical stage, therapy efficacy, tumor metastatis and patient survival in ovarian cancer. Anticancer Res 2004;24(3): 1973-9.
24. Kaya A, Gülbay BE, Gürkan ÖU, Çelik G, Savaş H, Savaş I. [Elevated levels of circulating matrix metalloproteinase-9 in non-small cell lung cancer]. Tuberk Toraks 2003;51(4): 380-4.
25. Ondo K, Sugio K, Yamazaki K, Yamaguchi M, Yano T, Yoshino I, et al. The significance of serum active matrix metalloproteinase-9 in patients with non-small cell lung cancer. Lung Cancer 2004;46(2):205-13.
26. Güney N, Soydinç HO, Derin D, Tas F, Camlica H, Duranyildiz D, et al. Serum levels of intercellular adhesion molecule ICAM-1 and E-selectin in advanced stage non-small cell lung cancer. Med Oncol 2008;25(2):194-200.
27. Sprenger A, Schardt C, Rotsch M, Zehrer M, Wolf M, Havemann K, et al. Soluable intercellular adhesion molecule-1 in patients with lung cancer and benign lung disease. J Cancer Res Clin Oncol 1997;123(11-12): 632-8.
28. Brattstrom D, Bergqvist M, Larsson A, Holmertz J, Hesselius P, Rosenberg L, et al. Basic fibroblast growth factor and vascular endothelial growth factor in sera from non-small cell lung cancer patients. Anticancer Res 1998;18(2A):1123-7.
29. Takigawa N, Segawa Y, Fujimoto N, Hotta K, Eguchi K. Elevated vascular endo¬thelial growth factor in sera of patients with lung cancer. Anticancer Res 1998;18(2B):251-4.